cephalexinmonohydrate , 98% , 23325-78-2

CAS NO.：23325-78-2

Empirical Formula: C16H19N3O5S

Molecular Weight: 365.4

MDL number: MFCD00167148

EINECS: 629-748-1

PRODUCT Properties

• Melting point: >161°C (dec.)
• refractive index: 154 ° (C=0.5, H2O)
• storage temp.: Keep in dark place,Sealed in dry,Room Temperature
• solubility: NH₄OH 1 M: 50 mg/mL, clear, yellow
• form: solid
• color: White to Light Beige
• Water Solubility: 13.5g/L(25 ºC)
• Merck: 14,1974
• BRN: 965503
• Stability: Unstable in Solution
• InChIKey: AVGYWQBCYZHHPN-KJTIIWGRSA-N

Description and Uses

Cephalexin was first synthesized in 1967 by Glaxo Research Laboratories and first produced on an industrial scale by Eli Lilly & Co. in the same year. It is a deacetoxylated derivative of cephaloglycin that is not metabolized in vivo. When administered orally, it shows a much higher serum concentration and much lower tendency to induce diarrhea than cephaloglycin. Cephalexin has been used widely and is the most popular orally active antibiotic in the world for treatment of respiratory tract, urinary tract, surgical, ear and nose, and other infections caused by Staphylococcus, Streptococcus, Escherichia coli, Klebsiella, Enterobacter, and Proteus.

Semi-synthetic cephalosporin antibiotic.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• Hazard Codes: Xn
• Risk Statements: 42/43
• Safety Statements: 22-36/37-45-24/25
• WGK Germany: 3
• RTECS: XI0350000
• HS Code: 29419052
• Toxicity: LD50 in mice, rats (g/kg): 1.6-4.5, >5.0 orally; 0.4-1.3, >3.7 i.p. (Welles)